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Abstract
Non-small cell lung cancer (NSCLC) frequently metastasizes to bone, which is associated with significant morbidity
and a dismal prognosis. RUNX3 functions as a tumour suppressor in lung cancer and loss of expression occurs
more frequently in invasive lung adenocarcinoma than in pre-invasive lesions. Here, we show that RUNX3 and
RUNX3-regulated chemokines are linked to NSCLC-mediated bone resorption. Notably, the receptor activator of
nuclear factor-𝛋B ligand (RANKL)/osteoprotegerin (OPG) ratio, an index of osteoclastogenic stimulation, was
significantly increased in human osteoblastic cells treated with conditioned media derived from RUNX3-knockdown
NSCLC cells. We aimed to identify RUNX3-regulated factors that modify the osteoblastic RANKL/OPG ratio and
found that RUNX3 knockdown led to CCL5 up-regulation and down-regulation of CCL19 and CXCL11 in NSCLC
cells. Tumour size was noticeably increased and more severe osteolytic lesions were induced in the calvaria and tibiae
of mice that received RUNX3-knockdown cells. In response to RUNX3 knockdown, serum and tissue levels of CCL5
increased, whereas CCL19 and CXCL11 decreased. Furthermore, CCL5 increased the proliferation, migration, and
invasion of lung cancer cells in a dose-dependent manner; however, CCL19 and CXCL11 did not show any significant
effects. The RANKL/OPG ratio in osteoblastic cells was increased by CCL5 but reduced by CCL19 and CXCL11. CCL5
promoted osteoclast differentiation, but CCL19 and CXCL11 reduced osteoclastogenesis in RANKL-treated bone
marrow macrophages. These findings suggest that RUNX3 and related chemokines are useful markers for the
prediction and/or treatment of NSCLC-induced bone destruction.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Non-small cell lung cancer (NSCLC) accounts for
approximately 80% of lung cancers and has an overall
5-year survival rate of only 15%. Bone metastases
occur in 30–40% of NSCLC patients and develop
skeletal-related events, resulting in negative effects on
quality of life and survival [1]. Lung cancer metastasis
to bone is the primary cause of osteolytic lesions in
the spine, ribs, pelvis, and proximal long bones. These
lesions arise due to functional interactions between
cancer cells and bone cells [2,3]. Localized cancer cells
within the bone produce several osteoclastogenic factors
directly or via cancer–stroma interactions. These factors
converge on pre-osteoblasts/stromal cells to increase
the expression of receptor activator of nuclear factor-κB
ligand (RANKL) and/or to decrease the expression
of its decoy receptor osteoprotegerin (OPG). RANKL
binds to its receptor RANK on osteoclast precursors
and induces osteoclastogenesis, causing increased bone
resorption [3–5]. The growth factors released from
the degraded bone matrix further stimulate the growth
of cancer cells and promote the secretion of their
osteolytic factors, leading to a ‘vicious cycle’ of bone
destruction and metastatic outgrowth [5,6]. Unfortu-
nately, little is known about the factors involved in lung
cancer-mediated bone destruction and the mechanisms
by which osteolytic lesions are formed.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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Human runt-related transcription factor (RUNX) pro-
teins have pivotal functions in normal development
and the development of neoplasia [7]. In cancer-related
bone diseases, RUNX2 has taken centre stage as a
pro-metastatic factor and potential target for controlling
metastatic breast and prostate cancer cells in the bone
microenvironment because it is critical for the regula-
tion of genes that support bone formation and because it
is abnormally expressed in tumours with bone tropism
[8]. In contrast, RUNX3 acts a tumour suppressor in
most cancers [9]. Aberrant methylation of the RUNX3
gene promoter occurs during carcinogenesis and is more
frequent in invasive than in pre-invasive lung adenocar-
cinoma lesions [10,11]. RUNX3 methylation correlates
with clinical stage, lymph node metastasis, and degree
of differentiation in NSCLC [12]. In addition, murine
Runx3 cooperates with Runx2 to induce chondrocyte
maturation [13], and increased RUNX3 promoter methy-
lation is associated with aggressive chondrosarcoma and
decreased survival time [14].
Chemokines are small secreted proteins that attract
and activate cells to specific locations in the body under
both physiological and pathological conditions [15].
These proteins have a direct influence on tumour growth,
invasion, and specific homing to metastatic sites [16],
and they also mediate the crosstalk between tumour
cells and bone microenvironment [17]. In lung cancer,
tumour-derived IL-8 induces osteoclast differentiation
via RANKL-dependent and RANKL-independent path-
ways, thereby stimulating osteolysis [18]. In contrast,
CCL22 production by differentiating osteoclasts pro-
motes the bone metastasis of lung cancer cells express-
ing its receptor CCR4 [19].
The aim of this study was to determine whether
RUNX3 and RUNX3-regulated chemokines could serve
as predictive markers and/or therapeutic targets of lung
cancer-mediated bone diseases. We investigated the
role of RUNX3 in NSCLC-mediated bone destruc-
tion and examined the effects of the RUNX3-regulated
chemokines CCL5, CCL19, and CXCL11 on cancer
cells, osteoblasts, and osteoclasts.
Materials and methods
Supplementary materials and methods include more
details of reagents, antibodies, animals, cell culture,
western blot analysis, RUNX3 knockdown, qRT-PCR,
RT-PCR, PCR array of human chemokines and their
receptors, and public database analysis.
Preparation of conditioned medium (CM)
shNC or shRUNX3 A549 and H838 cells were seeded at
2× 106 cells per 100-mm dish and incubated overnight.
The culture media were replaced with serum-free
DMEM/F12 and the cells were cultured for 24 h. Cul-
ture media were collected and centrifuged at 500 g for
5min. The supernatant (CM) was used for subsequent
experiments.
Quantitative real-time RT-PCR (qRT-PCR), ELISA,
and western blot
hFOB1.19 cells (5× 106 cells per dish) were treated with
CM for 6 h or incubated in serum-free media with the
indicated concentrations of human CCL5, CCL19, or
CXCL11 for 6 h. RANKL and OPG mRNA expression
was examined by qRT-PCR as described in the
Supplementary materials and methods. CCL5, CCL19,
and CXCL11 levels in CM were measured with Quan-
tikine human CCL5/RANTES and CXCL11/I-TAC
immunoassay kits (R&D Systems, Minneapolis, MN,
USA) and the CCL19 ELISA kit (Abnova, Taipei City,
Taiwan) following the manufacturers’ protocols. The
total protein in the CM was determined using BCA
protein assay reagents (Pierce, Rockford, IL, USA).
For western blotting, hFOB1.19 cells were incubated
for 6 h in serum-free medium containing 75% CM plus
neutralizing antibodies against human CCL5, CCL19,
or CXCL11. Cells were also treated with human CCL5,
CCL19, or CXCL11 at the indicated concentrations.
RANKL and OPG protein expression was determined
with their specific primary antibodies as described in
the Supplementary materials and methods.
A murine calvarial model of cancer-associated bone
invasion and osteolysis
All animal experiments were approved by the Insti-
tutional Animal Care and Use Committee of the
Department of Laboratory Animal Resources, Yonsei
Biomedical Research Institute, Yonsei University
College of Medicine (Approval No 2012–0044,
2012–0045). Six-week-old female BALB/c nude mice
were randomly divided into three groups, with nine
mice per group. shNC or shRUNX3 A549 cells (1× 107
cells per 100 μl of PBS) were injected subcutaneously
over the calvaria of the mice using a 1-ml syringe with
a sterile 26-gauge needle. Control mice were injected
with PBS alone. The volumes of tumours over the
calvaria were measured twice per week using a digital
electric caliper for 46 days and calculated according to
the formula (a× b2)/2, where a is the longest diameter
and b is the shortest diameter of the tumour. On day 46,
blood, calvaria, and tumours were collected.
A murine intratibial model of cancer-associated
bone resorption
Five-week-old female BALB/c nude mice were ran-
domly divided into three groups, with seven mice per
group. shNC or shRUNX3 A549 cells (1× 106 cells per
50 μl of HBSS) were injected into the bone marrow of
the right tibia through the femorotibial cartilage using
a Hamilton syringe with a sterile 27-gauge needle. Con-
trol mice were injected with HBSS alone. On day 49, the
mice were anaesthetized for μCT analysis of the tibiae.
Blood and tibiae were collected.
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μCT imaging and bone structure analysis
Bone morphometric parameters of the calvaria or tibiae
were determined using a μCT analyser (SkyScan 1076;
SkyScan, Aartselaar, Belgium) with NRecon software
(SkyScan). Two-dimensional (2D) images were used to
generate 3D reconstructions with the software supplied
with the instrument [20,21].
Histological and immunohistochemical examination
Sections of calvaria and tibiae were prepared and
stained with haematoxylin and eosin (H&E) as
described previously [20,22]. To detect osteoclasts,
sections were stained for TRAP using the Acid Phos-
phatase Leukocyte Kit (Sigma-Aldrich, St Louis, MO,
USA). Multinucleated TRAP-positive cells along the
tumour–bone interface were observed via microscopy
(original magnification× 100). For immunohisto-
chemical staining, the sections were deparaffinized,
rehydrated, and treated with 3% hydrogen peroxide
for 15min at room temperature followed by treat-
ment with goat serum for 30min. The sections were
incubated overnight at 4 ∘C with primary antibodies
(diluted 1:50 or 1:300) against RUNX3, CCL5, CCL19,
and CXCL11. The sections were treated with HRP-
conjugated secondary anti-rabbit IgG antibodies (diluted
1:100) for 30min. HRP was developed using the DAB
system (Lab Vision Corporation, Fremont, CA, USA).
The sections were counterstained with haematoxylin,
dehydrated, mounted, and examined via microscopy.
Determination of serum biochemical parameters
Blood samples were maintained at room temperature
for 1 h and then centrifuged at 900 g for 20min to
obtain serum. The serum levels of calcium, alkaline
phosphatase (ALP), and osteoclast-derived TRAP5b
were estimated using the QuantiChrome calcium assay
kit, the ALP assay kit (BioAssay Systems, Hayward,
CA, USA), and a mouse TRAP assay kit (Immunodiag-
nostic Systems, Scottsdale, AZ, USA) according to the
manufacturers’ instructions. The CCL5, CCL19, and
CXCL11 levels in the serum were measured using their
respective kits.
Cell viability, BrdU incorporation,
and migration/invasion
The viability of shNC or shRUNX3 A549 cells was
determined using the trypan blue exclusion assay, and
that of bone marrow macrophages (BMMs) was mea-
suredwith theMTT assay. DNA synthesis wasmeasured
in shNC or shRUNX3 A549 cells using a BrdU cell
proliferation ELISA kit (Roche Diagnostics, Penzberg,
Germany). The migratory and invasive abilities of shNC
or shRUNX3 A549 cells were evaluated using a scratch
migration assay and transwell invasion assay, respec-
tively [21].
Osteoclast differentiation assay
BMMs (5× 104 cells per well) were cultured in α-MEM
containing 10% FBS, 30 ng/mlM-CSF, and 100 ng/ml
RANKL in the absence or presence of CCL5, CCL19, or
CXCL11 at the indicated concentrations for 5 days. The
number of osteoclasts was determined by counting the
number of multinucleated (≥3 nuclei) TRAP-positive
cells [20,22].
Statistical analysis
The data are expressed as means± standard error (SE).
Statistical analyses were performed using one-way anal-
ysis of variance (ANOVA) and Student’s t-test to evalu-
ate differences between groups. p< 0.05 was considered
statistically significant.
Results
RUNX3 knockdown in NSCLC cells increased
the osteoblastic RANKL/OPG ratio by modulating
the production of CCL5, CCL19, and CXCL11
To determine the role of RUNX3 in lung cancer-
mediated bone destruction, we detected RUNX3 expres-
sion in two of four NSCLC cell lines (Supplementary
Figure 1A) and established stable RUNX3-knockdown
(shRUNX3) A549 and H838 cells via lentiviral
vector-mediated transduction with RUNX3 shRNA
(Supplementary Figure 1B). Treatment with CM from
shNC (control) A549 cells increased the RANKL/OPG
ratio in hFOB1.19 osteoblastic cells, an index of osteo-
clastogenesis stimulation, by inducing RANKL mRNA
and reducing OPG mRNA. Moreover, RANKL mRNA
and the RANKL/OPG ratio were increased at a sub-
stantially higher level in response to treatment with
CM from shRUNX3 A549 cells (Figure 1A). RUNX3
knockdown in H838 cells also resulted in substantial
increases in osteoblastic RANKL mRNA expression
and the RANKL/OPG ratio (Figure 1B). In contrast,
RUNX3 knockdown slightly increased the viability
(Supplementary Figure 1C), migration (Supplementary
Figure 1D), and invasion (Supplementary Figure 1E) of
A549 lung cancer cells, as well as the amount of newly
synthesized DNA in proliferating cells (Supplementary
Figure 1C). These results suggest that RUNX3 knock-
down in NSCLC cells may influence the production of
factors that alter osteoblastic RANKL expression rather
than their metastatic ability.
To identify RUNX3-regulated factors in NSCLC
cells that control osteoblastic RANKL expression, we
examined the mRNA levels of chemokines and their
receptors in response to RUNX3 knockdown in A549
cells. RUNX3 knockdown resulted in up-regulation of
CCL5 and TCP10 and down-regulation of CXCL11,
CCL19, and HCAR1 (Supplementary Table 1). ELISA
analyses revealed that the level of secreted CCL5
increased by 1.8-fold (from 17.4 to 30.6 pg) but that
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 237: 520–531
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Figure 1. RUNX3 knockdown in NSCLC cells substantially increased the osteoblastic RANKL/OPG ratio by modulating NSCLC-derived
chemokines. (A, B) The mRNA levels of RANKL and OPG were determined via qRT-PCR in hFOB1.19 cells treated with 50% and 75%
CM from shNC or shRUNX3 A549 (A) and H838 cells (B) for 6 h. Mean± SE; #p< 0.05, ##p< 0.01 versus osteoblastic cells without CM;
*p< 0.05 versus osteoblastic cells treated with shNC cell-derived CM. (C) CCL5, CCL19, and CXCL11 in culture media of shNC or shRUNX3
A549 and H838 cells. Mean± SE; *p< 0.05 versus shNC cells. (D, E) hFOB1.19 osteoblastic cells were treated with 75% CM of A549 cells
(D) or H838 cells (E) and the indicated concentrations of neutralizing antibodies against CCL5, CCL19 or CXCL11 for 6 h. RANKL and OPG
protein were investigated via western blot analysis. The images are representative of three independent experiments. The graphs illustrate
the ratio of the densitometric intensity of RANKL to that of OPG after normalization to β-actin. Mean± SE; #p< 0.01 versus osteoblastic
cells without CM and specific antibodies against chemokines; *p< 0.05 versus CM-treated osteoblastic cells.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 237: 520–531
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CCL19 and CXCL11 secretion decreased by 0.8-fold
(from 2.4 to 2.1 pg) and 0.7-fold (from 22.7 to 16.1 pg),
respectively, in culture medium from shRUNX3 A549
cells. Similar to A549 cells, RUNX3 knockdown in
H838 cells also caused an increase in the level of CCL5
in the culture medium by 1.8-fold (from 16.3 to 29.3 pg)
but decreased CCL19 and CXCL11 levels by 0.9-fold
(from 2.8 to 2.4 pg) and 0.7-fold (from 26.9 to 18.0 pg),
respectively (Figure 1C). In addition, RT-PCR data
(Supplementary Figure 2A) and western blot analysis
(Supplementary Figure 2B) indicated that RUNX3
knockdown increased CCL5mRNA and protein expres-
sion but decreased the mRNA and protein expression of
CCL19 and CXCL11. Consistent with the array data,
RUNX3 knockdown did not affect the mRNA levels of
CCR1, CCR3, CCR4, CCR5 (CCL5 receptors), CCR7
(a CCL19 receptor), CXCR3, or CXCR7 (CXCL11
receptors) (Supplementary Figure 3A) and did not
change the protein levels of CCR5, CCR7, or CXCR3,
which are recognized to be major receptors for CCL5,
CCL19, and CXCL11, respectively, in A549 and H838
cells (Supplementary Figure 3B).
To verify whether CCL5, CCL19, and CXCL11
are NSCLC-derived factors that modulate osteoblas-
tic RANKL and OPG expression, hFOB1.19 cells
were treated with the respective antibodies against
these chemokines in the presence of conditioned media.
Neutralization with CCL5 antibody blocked the increase
in the RANKL/OPG ratio in hFOB1.19 osteoblastic
cells stimulated with A549 cell-derived CM. Treat-
ment with CCL19 or CXCL11 antibody increased the
RANKL/OPG ratio (Figure 1D and Supplementary
Figure 4A). CCL5, CCL19, and CXCL11 antibodies
had very similar effects on RANKL andOPG expression
in osteoblastic cells stimulated with H838 cell-derived
CM compared with osteoblastic cells exposed to
A549 cell-derived CM (Figure 1E and Supplementary
Figure 4B).
RUNX3 knockdown increased lung
cancer-associated bone destruction in mice
To determine whether RUNX3 and RUNX3-regulated
chemokines are associated with bone invasion in human
Figure 2. RUNX3 knockdown promoted tumour growth and caused bone destruction in mouse calvaria inoculated with NSCLC cells. shNC
or shRUNX3 A549 cells (1× 107 per 100 μl of PBS) were injected subcutaneously over the calvaria. Control mice were injected with PBS
alone. On day 46, blood was collected and the mice were euthanized. (A) Tumour volumes and photos of tumour-bearing mouse heads. (B)
H&E and TRAP staining of calvarial tissues. T= tumour; B= bone; Br= brain. Arrowheads denote osteoclasts (original magnification× 100).
(C) 3D images were reconstructed from the 2D images of μCT using the software supplied with the instrument. (D) Bone morphometric
parameters BV/TV (%) and BS/TV (1/mm) in mouse calvaria using μCT. (E) Serum levels of bone turnover markers Ca2+, ALP, and TRAP5b, and
(F) RUNX3-regulated chemokines. (G) Immunohistochemical analyses of RUNX3, CCL5, CCL19, and CXCL11 in the tumour tissues of mouse
calvaria (original magnification× 200). Means± SE. *p< 0.05, **p< 0.005 versus shNC A549 cell-inoculated mice.
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lung cancer, we established two murine models. In mice
in which A549 lung cancer cells were subcutaneously
injected onto the surface of calvaria, tumour volumes
increased more dramatically in response to RUNX3
knockdown (Figure 2A). Histological examination
indicated that invasive tumour growth and severe bone
resorption occurred in mice inoculated with shRUNX3
cells, whereas cancer cell invasion and osteolysis were
hardly detected in mice inoculated with shNC cells.
TRAP staining demonstrated that bone-resorbing osteo-
clasts (dark brown) were produced at the tumour–bone
interface in the calvaria of shRUNX3 cell-inoculated
mice compared with shNC cell-inoculated mice
(Figure 2B). shRUNX3 cell-mediated osteolysis was
confirmed via reconstructed 3D images of the μCT
data (Figure 2C) as well as significant reductions in
bone morphometric parameters, per cent bone volume
(bone volume/tissue volume, BV/TV), and bone surface
density (bone surface/tissue volume, BS/TV) in the
calvaria inoculated with RUNX3-knockdown cells
(Figure 2D). Additionally, the serum levels of calcium,
ALP, and TRAP5b (markers of bone turnover) were
significantly elevated in the shRUNX3 cell-inoculated
mice (Figure 2E). Consistent with the results of the in
vitro study, the serum level of CCL5 was significantly
increased and those of CCL19 and CXCL11 were
significantly decreased in the shRUNX3 cell-inoculated
mice (Figure 2F). Using immunohistochemical analy-
sis, we verified the increased expression of CCL5 and
reduced expression of CCL19 and CXCL11 in tumour
tissues from shRUNX3 cell-inoculated mice compared
with shNC cell-inoculated mice (Figure 2G).
The intratibial injection of cancer cells in mice has
been known to cause bone lesions similar to those
observed in cancer patients [23]. Radiophotography
and 3D images of the μCT data showed that osteolytic
lesions were induced in the tibiae of shNC cell-injected
mice and that RUNX3-knockdown cells aggravated
osteolysis (Figure 3A). In bone morphometric analyses
of the tibiae, the per cent bone volume (BV/TV), bone
surface density (BS/TV), trabecular thickness (Tb.Th),
and trabecular number (Tb.N) decreased, while the
trabecular separation (Tb.Sp) and structure model index
(SMI) increased in shNC cell-injected mice compared
with control mice. RUNX3 knockdown resulted in a
greater reduction of BV/TV, BS/TV, Tb.Th, and Tb.N,
and a greater elevation of Tb.Sp and SMI (Figure 3B).
Histological examination revealed that shRUNX3 cells
invaded the tibiae more aggressively than shNC cells
and that tumour volumes were significantly increased
in shRUNX3 cell-inoculated mice compared with
shNC cell-inoculated mice. Increased numbers of
TRAP-positive mature osteoclasts were present within
the bone surface close to the invasive tumour in the
shRUNX3 cell-inoculated tibiae compared with the
shNC cell-inoculated tibiae (Figure 3C). The serum
levels of calcium, ALP, and TRAP5b were also sig-
nificantly increased in shRUNX3 cell-inoculated mice
compared with shNC cell-inoculated mice (Figure 3D).
CCL5 was significantly elevated and CCL19 and
CXCL11 did not change significantly in the sera of
shRUNX3 cell-inoculated mice (Figure 3E). Immuno-
histochemical analysis showed that CCL5 increased
substantially, whereas CCL19 and CXCL11 decreased
in response to RUNX3 knockdown (Figure 3F). How-
ever, RANKL and OPG (Supplementary Figure 5A)
as well as RUNX2 (Supplementary Figure 5B) did not
show measurable changes after RUNX3 knockdown in
both murine models. Therefore, the presence of oste-
olytic lesions caused by lung cancer cells was closely
associated with RUNX3-regulated CCL5, CCL19, and
CXCL11, as well as the expression of RUNX3.
CCL5 stimulated the proliferation, migration,
and invasion of NSCLC cells
We evaluated the effects of CCL5, CCL19, and CXCL11
on lung cancer. Cell viability, BrdU incorporation, cell
migration, and cell invasion were increased in both
shNC and shRUNX3 cells treated with CCL5, and this
increase was greater in shRUNX3 cells than in shNC
cells (Figure 4). By contrast, CCL19 and CXCL11 did
not substantially affect the proliferation, migration, or
invasion of either shNC or shRUNX3 cells.
CCL5, CCL19, and CXCL11 regulated osteoblastic
RANKL and OPG expression and RANKL-induced
differentiation of osteoclast precursors
Next, we determined the effect of CCL5, CCL19,
and CXCL11 on the osteoclastogenesis-associated
factors RANKL and OPG in hFOB1.19 osteoblastic
cells. Real-time RT-PCR (Figure 5A and Supplemen-
tary Figure 6A) and western blot analysis (Figure 5B
and Supplementary Figure 6B) revealed that CCL5
caused an increase in the RANKL/OPG ratio via the
up-regulation of RANKL mRNA and protein expression
and/or the down-regulation of OPG mRNA and protein
expression in a dose-dependent manner. In contrast,
CCL19 and CXCL11 decreased the RANKL/OPG ratio
by down-regulating RANKL mRNA and protein expres-
sion and/or up-regulating OPG mRNA and protein
expression. However, CCL5, CCL19, and CXCL11 did
not affect RANKL and OPG in A549 (Supplementary
Figure 7A) and H838 NSCLC cells (Supplementary
Figure 7B).
We further examined whether CCL5, CCL19, and
CXCL11 could directly induce osteoclast formation
in BMMs. In BMMs treated with CCL5, CCL19, or
CXCL11 for 5 days, CCL5 increased cell viability
by 15% at a concentration of 7 μM (p< 0.05); how-
ever, CCL19 and CXCL11 did not affect cell viability.
CCL5 also stimulated the formation of TRAP-positive
osteoclasts by 15% at a concentration of 7 μM; how-
ever, at the same concentration, CCL19 and CXCL11
markedly decreased osteoclast formation by 32% and
41%, respectively, in RANKL-treated BMMs. Interest-
ingly, CCL5, CCL19, or CXCL11 alone did not induce
osteoclast differentiation from BMMs in the absence of
RANKL (Figure 5C).
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Figure 3. RUNX3 knockdown aggravated bone destruction in mouse tibiae inoculated with NSCLC cells. A549 cells (1× 106 cells per
50 μl of HBSS) were injected into the bone marrow of the tibiae through the femorotibial cartilage. Control mice were injected with
HBSS alone. On day 49, the mouse tibiae were analysed using μCT and blood and tibiae were collected. (A) Radiophotographs and 3D
images of μCT data from the tibiae. Arrowheads indicate osteolytic foci. (B) The bone morphometric parameters of mouse tibia were
determined using μCT. (C) H&E (original magnification× 50) and TRAP staining (original magnification× 100). Tumour area was measured
in H&E-stained tissues. T= tumour; B= bone. Arrowheads denote osteoclasts (D, E) Serum levels of bone turnover markers Ca2+, ALP,
and TRAP5b, and RUNX3-regulated chemokines. (F) RUNX3, CCL5, CCL19, and CXCL11 in tumour tissues of mouse tibiae were detected
via immunohistochemical analysis (original magnification× 200). Means± SE. #p< 0.05, ##p< 0.005 versus control mice; *p< 0.05 versus
shNC A549 cell-inoculated mice.
Discussion
The majority of advanced-stage lung cancer patients
die within 18 months of diagnosis; the median survival
time of lung cancer patients with bone metastases is
less than 1 year [1,24]. Bone metastases are usually
diagnosed using bone imaging techniques; however,
the current imaging methods are not sufficiently sensi-
tive for the detection of bone metastases and can also
be invasive and expensive [25]. A number of clini-
cal trials have focused on factors derived from bone
metabolism rather than tumour-derived factors, and
bisphosphonates, bone resorption inhibitors, and deno-
sumab, a monoclonal antibody against RANKL, have
been applied for the treatment of patients with bone
metastases [25,26]. However, bisphosphonates and
RANKL-targeted therapies can cause serious adverse
events such as hypocalcaemia, osteonecrosis of the jaw,
and renal toxicity. Thus, there is a significant need for
the prediction of bone metastasis and the establishment
of more effective therapeutic strategies. More recent
studies have focused on cancer-derived factors that
stimulate differentiation and activation of osteoclasts
either directly or through osteoblasts [10,27]. We
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Figure 4. CCL5 enhanced the proliferation, migration, and invasion of NSCLC cells. (A) Trypan blue exclusion of A549 (1× 105 cells per
ml) treated with the indicated concentrations of human CCL5, CCL19, or CXCL11 for 48 h. (B) BrdU incorporation of cells (1× 104 cells
per well) exposed to the indicated concentrations of chemokines for 24 h. (C) Cell migration in RPMI1640 medium containing 2% FBS,
10 μg/ml mitomycin C, and the indicated concentrations of chemokines for 24 h. (D) A549 (1× 105 cells per 0.1ml) invasion through
Matrigel-coated filter. Cells were suspended in serum-free medium containing 0.01% BSA. The lower chamber was filled with 600 μl of
medium containing 10% FBS and/or human chemokines at the indicated concentrations. Invaded cells were counted after 48 h. Means± SE.
#p< 0.05, ##p< 0.005 versus cells without chemokines; *p< 0.05, **p< 0.005 versus shNC cells.
assessed whether the cancer-derived factors RUNX3
and RUNX3-regulated chemokines could be useful for
the detection and management of lung cancer bone
metastasis.
We found that RUNX3 knockdown in RUNX3-
expressing NSCLC cells increased the RANKL/OPG
ratio in osteoblastic cells, rather than affecting the
proliferation, migration, and invasion of the cancer
cells themselves, indicating that these lung cancer cells
secreted factors that modified RANKL and OPG expres-
sion in osteoblastic cells and that the expression of these
factors was regulated by RUNX3. The relative ratio of
RANKL/OPG in the bone marrow microenvironment
is one of the principal factors that regulate osteoclast
formation and activation [28]. In patients with cancers
that metastasize to bone, an increased RANKL/OPG
ratio results in a higher risk of osteolytic lesions and
mortality [29–31].
Chemokines act as key mediators that facilitate the
interplay between tumour cells and their surround-
ing cells in the microenvironment [32], and some
chemokines play critical roles in bone destruction
via cancer cells with bone tropism [33]. Therefore,
we analysed the expression of chemokines and their
receptors in response to RUNX3 knockdown to deter-
mine the factors that regulate osteoblastic RANKL
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Figure 5. CCL5, CCL19, and CXCL11 altered RANKL and OPG expression in osteoblastic cells and RANKL-induced osteoclast differentiation
in BMMs. Human osteoblastic hFOB1.19 cells were treated with the indicated concentrations of human CCL5, CCL19, or CXCL11 for 6 h.
(A) RANKL and OPG mRNA analysed via qRT-PCR. GAPDH was used as an endogenous control. (B) Western blots of total cell lysates
(representative of three independent experiments). β-actin served as a loading control. Graphs show densitometric intensity ratios of
RANKL/OPG after normalization. Means± SE; *p< 0.01 versus osteoblastic cells without chemokines. (C) Mouse BMMs (5× 104 cells
per well) cultured for 5 days in α-MEM containing 10% FBS and 30 ng/mlM-CSF, in the absence or presence of CCL5, CCL19, or
CXCL11 at the indicated concentrations and in the absence (control) or presence of 100 ng/ml RANKL. TRAP staining was performed to
detect osteoclasts (original magnification× 100). TRAP-positive multinucleated cells (≥3 nuclei) were counted as osteoclasts. Means± SE;
*p< 0.05, **p< 0.005 versus RANKL-treated BMMs.
and OPG expression in lung cancer cell-derived con-
ditioned media. RUNX3 knockdown resulted in the
up-regulation of CCL5 and TCP10 mRNA and the
down-regulation of CXCL11, CCL19, and HCAR1
mRNA in A549 cells. CCL5 contributes to the migra-
tion and invasion of human lung, breast, and oral cancer
cells [34–37]. Clinical evidence has demonstrated that
elevated levels of tissue or plasma CCL5 are useful for
predicting survival as well as unfavourable outcomes
in cancer patients [38–40]. Among the down-regulated
chemokines in RUNX3-knockdown A549 cells, CCL19
showed IFN-γ-dependent anti-tumour responses in
a murine lung cancer model and reduced tumouri-
genicity in a murine ovarian carcinoma model [41,42].
CXCL11 is characterized by its anti-tumoural and
anti-inflammatory activities because it acts as an
angiostatic regulator and mediates the infiltration of T
lymphocytes and natural killer cells [43,44]. The roles
of hydroxycarboxylic acid receptor 1 (HCAR1) and
T-complex 10 homologue (TCP10) in human cancer
progression remain unknown. Thus, we selected CCL5,
CCL19, and CXCL11 as NSCLC-derived factors that
influence the osteoblastic RANKL/OPG ratio.
We confirmed that the amount of secreted CCL5
increased, while that of CCL19 and CXCL11 decreased
in response to RUNX3 knockdown in both NSCLC cell
lines. Neutralization with specific antibodies indicated
that these chemokines may serve as NSCLC-derived
factors regulating the RANKL/OPG ratio in osteoblas-
tic cells: treatment with CCL5 antibody reduced the
conditioned medium-induced increase in the
RANKL/OPG ratio, whereas treatment with anti-
bodies against CCL19 and CXCL11 increased the
RANKL/OPG ratio. Additionally, RUNX3 knockdown
increased tumour volumes and induced severe osteolytic
lesions in the calvaria and tibiae of A549 cell-injected
mice, as supported by examinations of bone morpho-
metric parameters, the serum levels of biochemical
bone turnover markers, and histological analyses of
bone invasion. Serum and tissue levels of CCL5 were
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elevated, while those of CCL19 and CXCL11 were
reduced in response to RUNX3 knockdown. These
results suggest that the loss of RUNX3 may exacerbate
bone invasion and osteolysis, and that this phenomenon
is closely associated with the induction of CCL5 and
the inhibition of CCL19 and CXCL11 in NSCLC
cells.
Based on these results, we further investigated the
effects of CCL5, CCL19, and CXCL11 on NSCLC
cells, osteoblasts, and osteoclasts, which participate in
the vicious cycle of lung cancer-induced bone destruc-
tion. CCL5 stimulated the proliferation, migration,
and invasion of RUNX3-knockdown lung cancer cells
compared with RUNX3-expressing cells, whereas
CCL19 and CXCL11 had no effect. CCL5 substantially
increased the RANKL/OPG ratio, while CCL19 and
CXCL11 decreased this ratio in osteoblastic cells.
Moreover, CCL5 stimulated osteoclast formation via
the increased viability of BMMs, whereas CCL19
and CXCL11 reduced osteoclast differentiation in
RANKL-treated BMMs. These results indicate that
lung cancer cell-derived CCL5 may act as an oste-
olytic factor but CCL19 and CXCL11 may possess
anti-osteoclastogenic activity.
Finally, we attempted to estimate the clinical sig-
nificance of RUNX3 and chemokines. Because lung
metastases to bone are rarely resected and were not
available for study, we analysed TCGA microarray
data and online bioinformatics tools in KM plotter
[45]. RUNX3 expression was significantly lower in
NSCLC tissues than in normal tissues, and in advanced
stages (stages III and IV) with distant metastasis
than in early stages (stages I and II) (Supplementary
Figure 8A). The 5-year overall survival was signifi-
cantly higher in patients with high levels of RUNX3
and RUNX3-regulated chemokines (Supplementary
Figure 8B). High levels of CCL5 and low levels of
RUNX3, CCL19, and CXCL11 may be correlated
with poor post-progression survival (Supplementary
Figure 8C).
CCL5 promotes the migration, invasion, and metasta-
sis in lung, breast, and prostate cancer cells [34–36,46].
In breast and gastric cancer, higher CCL5 expression
increased significantly the risk for disease progression
and reduced the overall survival of patients [38,47].
Plasma CCL5 levels were higher in the order of stages
IV, III, II, and I in patients with breast or cervical cancer
[48]. In contrast, stage I lung adenocarcinoma patients
with lower CCL5 mRNA expression had a higher mor-
tality [49]. This difference in tumour behaviour may
be worthy of future study. Further studies are also
required to obtain more significant data in clinical
samples.
In conclusion, RUNX3 and the RUNX3-regulated
chemokines CCL5, CCL19, and CXCL11 are closely
associated with NSCLC-induced osteolysis. There-
fore, RUNX3 expression and the levels of related
chemokines can serve as predictive markers and future
therapeutic targets for lung cancer-induced bone
destruction.
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